Clopidogrel single antiplatelet therapy

Preclinical

Clopidogrel single antiplatelet therapy is one of 21 therapeutic programs targeting Aortic Stenosis. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Aortic StenosisRecruiting

Aortic StenosisPreclinical

Recruiting

Competition

Competitive Landscape

25 competitors in Aortic Stenosis

#DrugCompanyPhaseTrials

Cialis

Eli Lilly

Approved

2 2

Lescol

Novartis

Approved

2 3

Aldactone

Pfizer

Approved

1 4

Zebeta

Teva

Approved

1 5

Plavix

Sanofi

Approved

1 6

Brilinta

AstraZeneca

Approved

1 7

Savaysa

Bayer Aspirin

Niacor

Viagra

VViatris Specialty LLC

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

PreclinicalRecruiting

Aortic Stenosis

NCT05493657

Clinical

Trials by Indication[1]

Aortic Stenosis1 trial

Aspirin Versus Clopidogrel for Leaflet Thrombosis Prevention in Patients Undergoing Transcatheter Aortic Valve Replacement: ACLO-TAVR Trial

Recruiting·YYonsei University·Preclinical·NCT05493657·270 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Clopidogrel single antiplatelet therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Clopidogrel single antiplatelet therapy. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Yonsei University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Preclinical[1]
Company: YYonsei University

Clopidogrel single antiplatelet therapy

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2027

Trials by Indication[1]

Aortic Stenosis1 trial

References

Drug Info

Quick Facts

Related News